Details of the Drug

General Information of Drug (ID: DME78OA)

• Drug Name: Biperiden
• Synonyms: Akineton; Beperiden; Biperidene; Biperideno; Biperidenum; Biperidine; Biperidene hydrochloride; KL 373; Akineton (TN);Biperidene [INN-French]; Biperideno [INN-Spanish]; Biperidenum [INN-Latin]; Biperiden (JAN/USP/INN); Biperiden [USAN:BAN:INN:JAN]; Biperiden [USAN:INN:BAN:JAN]; Alpha-5-Norbornen-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-Bicyclo(2.2.1)hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-(Bicyclo(2.2.1)hept-5-en-2-yl)-alpha-phenyl-1-piperidino propanol; 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol; 1-(Bicyclo(2.2.1)hept-5-en-2alpha-yl)-1-phenyl-3-piperidinopropanol; 1-(bicyclo[2.2.1]hept-5-en-2-yl)-1-phenyl-3-(piperidin-1-yl)propan-1-ol; 1-Bicycloheptenyl-1-phenyl-3-piperidino-propanol-1; 1-Piperidinepropanol, .alpha.-bicyclo[2.2.1]hept-5-en-2-yl-.alpha.-phenyl-, hydrochloride; 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1); 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1) [German]; 3-Piperidino-1-phenyl-1-bicycloheptenyl-1-propanol

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Approved	[1]

• Therapeutic Class: Antiparkinson Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 311.5
  Topological Polar Surface Area (xlogp); 4.3
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 2
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
  Bioavailability: The bioavailability of drug is 87% [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 12 mL/min/kg [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 24 hours [4]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.64211 micromolar/kg/day [5]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.097% [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 12 L/kg [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 1 mg/mL [2]
• Chemical Identifiers:
  Formula: C21H29NO
  IUPAC Name: 1-(2-bicyclo[2.2.1]hept-5-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol
  Canonical SMILES: C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O
  InChI: InChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2
  InChIKey: YSXKPIUOCJLQIE-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 2381
  ChEBI ID: CHEBI:3112
  CAS Number: 514-65-8
  DrugBank ID: DB00810
  TTD ID: D0B4TN
  INTEDE ID: DR2266

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Muscarinic acetylcholine receptor M1 (CHRM1)	TTZ9SOR	ACM1_HUMAN	Antagonist	[6]

Molecular Expression Atlas of This Drug

• The Studied Disease: Parkinson disease
• ICD Disease Classification: 8A00.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Muscarinic acetylcholine receptor M1 (CHRM1)	DTT	CHRM1	5.59E-01	0.19	0.41

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Biperiden

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Levodopa	DMN3E57	Moderate	Altered absorption of Biperiden due to GI dynamics variation caused by Levodopa.	Parkinsonism [8A00]	[16]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Biperiden and Orphenadrine.	Parkinsonism [8A00]	[17]

Coadministration of a Drug Treating the Disease Different from Biperiden (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Bethanechol	DMCLHO0	Moderate	Antagonize the effect of Biperiden when combined with Bethanechol.	Abnormal micturition [MF50]	[18]
Oliceridine	DM6MDCF	Moderate	Additive CNS depression effects by the combination of Biperiden and Oliceridine.	Acute pain [MG31]	[19]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Biperiden and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[20]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Biperiden and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[20]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Biperiden and Memantine.	Alzheimer disease [8A20]	[17]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Biperiden when combined with Rivastigmine.	Alzheimer disease [8A20]	[21]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Biperiden when combined with Donepezil.	Alzheimer disease [8A20]	[21]
Methylphenobarbital	DMDSWAG	Moderate	Additive CNS depression effects by the combination of Biperiden and Methylphenobarbital.	Anxiety disorder [6B00-6B0Z]	[19]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Biperiden and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[17]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Biperiden and Cariprazine.	Bipolar disorder [6A60]	[17]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Biperiden and Loperamide.	Bowel habit change [ME05]	[22]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Biperiden when combined with Acetylcholine.	Cataract [9B10]	[23]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Biperiden and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[24]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Biperiden and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[24]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Biperiden and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[24]
Dihydrocodeine	DMB0FWL	Moderate	Additive CNS depression effects by the combination of Biperiden and Dihydrocodeine.	Chronic pain [MG30]	[19]
Remifentanil	DMZTXCH	Moderate	Additive CNS depression effects by the combination of Biperiden and Remifentanil.	Corneal disease [9A76-9A78]	[19]
Arbutamine	DMCY8AF	Moderate	Increased risk of rapid heart rate by the combination of Biperiden and Arbutamine.	Coronary atherosclerosis [BA80]	[25]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Biperiden and Ethanol.	Cystitis [GC00]	[26]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Biperiden and Cyclobenzaprine.	Depression [6A70-6A7Z]	[17]
Isocarboxazid	DMAF1NB	Minor	Additive anticholinergic effects by the combination of Biperiden and Isocarboxazid.	Depression [6A70-6A7Z]	[19]
OPC-34712	DMHG57U	Moderate	Antagonize the effect of Biperiden when combined with OPC-34712.	Depression [6A70-6A7Z]	[27]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Biperiden and Clomipramine.	Depression [6A70-6A7Z]	[17]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Biperiden and Doxepin.	Depression [6A70-6A7Z]	[17]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Biperiden and Maprotiline.	Depression [6A70-6A7Z]	[17]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Biperiden and Esketamine.	Depression [6A70-6A7Z]	[28]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Biperiden and Mepenzolate.	Digestive system disease [DE2Z]	[20]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Biperiden and Oxybutynine.	Discovery agent [N.A.]	[17]
Heroin diacetylmorphine	DMDBWHY	Moderate	Additive CNS depression effects by the combination of Biperiden and Heroin diacetylmorphine.	Dissociative neurological symptom disorder [6B60]	[19]
Zonisamide	DM0DTF7	Major	Increased risk of hyperpyrexia by the combination of Biperiden and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[29]
Phenobarbital	DMXZOCG	Moderate	Additive CNS depression effects by the combination of Biperiden and Phenobarbital.	Epilepsy/seizure [8A61-8A6Z]	[19]
Cannabidiol	DM0659E	Moderate	Additive CNS depression effects by the combination of Biperiden and Cannabidiol.	Epileptic encephalopathy [8A62]	[19]
Diphenhydramine	DMKQTBA	Moderate	Additive anticholinergic effects by the combination of Biperiden and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[17]
Nadolol	DMW6GVL	Moderate	Antagonize the effect of Biperiden when combined with Nadolol.	Essential hypertension [BA00]	[30]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Biperiden and Solifenacin.	Functional bladder disorder [GC50]	[17]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Biperiden and Tolterodine.	Functional bladder disorder [GC50]	[17]
Ketoconazole	DMPZI3Q	Moderate	Decreased absorption of Biperiden due to altered gastric pH caused by Ketoconazole.	Fungal infection [1F29-1F2F]	[31]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Biperiden when combined with Pilocarpine.	Glaucoma [9C61]	[18]
Carvedilol	DMHTEAO	Moderate	Antagonize the effect of Biperiden when combined with Carvedilol.	Heart failure [BD10-BD1Z]	[30]
Chlorothiazide	DMLHESP	Minor	Altered absorption of Biperiden due to GI dynamics variation caused by Chlorothiazide.	Heart failure [BD10-BD1Z]	[32]
Acebutolol	DM0TI4U	Moderate	Antagonize the effect of Biperiden when combined with Acebutolol.	Hypertension [BA00-BA04]	[30]
Penbutolol	DM4ES8F	Moderate	Antagonize the effect of Biperiden when combined with Penbutolol.	Hypertension [BA00-BA04]	[33]
Nebivolol	DM7F1PA	Moderate	Antagonize the effect of Biperiden when combined with Nebivolol.	Hypertension [BA00-BA04]	[30]
Pindolol	DMD2NV7	Moderate	Antagonize the effect of Biperiden when combined with Pindolol.	Hypertension [BA00-BA04]	[30]
Trichlormethiazide	DMHAQCO	Minor	Altered absorption of Biperiden due to GI dynamics variation caused by Trichlormethiazide.	Hypertension [BA00-BA04]	[32]
Hydrochlorothiazide	DMUSZHD	Minor	Altered absorption of Biperiden due to GI dynamics variation caused by Hydrochlorothiazide.	Hypertension [BA00-BA04]	[32]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Biperiden and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[17]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Biperiden and Amantadine.	Influenza [1E30-1E32]	[34]
Amobarbital	DM0GQ8N	Moderate	Additive CNS depression effects by the combination of Biperiden and Amobarbital.	Insomnia [7A00-7A0Z]	[19]
ITI-007	DMUQ1DO	Moderate	Antagonize the effect of Biperiden when combined with ITI-007.	Insomnia [7A00-7A0Z]	[27]
R0-93877	DMM4U9G	Moderate	Antagonize the effect of Biperiden when combined with R0-93877.	Irritable bowel syndrome [DD91]	[35]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Biperiden when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[21]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Biperiden and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[36]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Biperiden and Lasmiditan.	Migraine [8A80]	[37]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Biperiden and Flibanserin.	Mood disorder [6A60-6E23]	[38]
Neostigmine	DM6T2J3	Moderate	Antagonize the effect of Biperiden when combined with Neostigmine.	Myasthenia gravis [8C6Y]	[39]
Edrophonium	DMCRQHB	Moderate	Antagonize the effect of Biperiden when combined with Edrophonium.	Myasthenia gravis [8C6Y]	[39]
Ambenonium	DMOP0BL	Moderate	Antagonize the effect of Biperiden when combined with Ambenonium.	Myasthenia gravis [8C6Y]	[39]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Biperiden and Phenindamine.	Nasopharyngitis [CA00]	[20]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Biperiden and Dimenhydrinate.	Nausea/vomiting [MD90]	[17]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Biperiden and Promethazine.	Nausea/vomiting [MD90]	[17]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Biperiden and Cyclizine.	Nausea/vomiting [MD90]	[20]
Metoclopramide	DMFA5MY	Moderate	Antagonize the effect of Biperiden when combined with Metoclopramide.	Nausea/vomiting [MD90]	[40]
Polythiazide	DMCH80F	Minor	Altered absorption of Biperiden due to GI dynamics variation caused by Polythiazide.	Oedema [MG29]	[32]
Levomethadyl Acetate	DM06HG5	Moderate	Additive CNS depression effects by the combination of Biperiden and Levomethadyl Acetate.	Opioid use disorder [6C43]	[19]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Biperiden and Apraclonidine.	Optic nerve disorder [9C40]	[41]
Oxymorphone	DM65AGJ	Moderate	Additive CNS depression effects by the combination of Biperiden and Oxymorphone.	Pain [MG30-MG3Z]	[19]
Levorphanol	DMGS80V	Moderate	Additive CNS depression effects by the combination of Biperiden and Levorphanol.	Pain [MG30-MG3Z]	[19]
Dezocine	DMJDB0Y	Moderate	Additive CNS depression effects by the combination of Biperiden and Dezocine.	Pain [MG30-MG3Z]	[19]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Biperiden and Flavoxate.	Pain [MG30-MG3Z]	[17]
Nalbuphine	DMOSQGU	Moderate	Additive CNS depression effects by the combination of Biperiden and Nalbuphine.	Pain [MG30-MG3Z]	[19]
Buprenorphine	DMPRI8G	Moderate	Additive CNS depression effects by the combination of Biperiden and Buprenorphine.	Pain [MG30-MG3Z]	[19]
Hydrocodone	DMQ2JO5	Moderate	Additive CNS depression effects by the combination of Biperiden and Hydrocodone.	Pain [MG30-MG3Z]	[19]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Biperiden and Methylscopolamine.	Peptic ulcer [DA61]	[17]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Biperiden and Levomepromazine.	Psychotic disorder [6A20-6A25]	[20]
Quetiapine	DM1N62C	Moderate	Antagonize the effect of Biperiden when combined with Quetiapine.	Schizophrenia [6A20]	[27]
Mesoridazine	DM2ZGAN	Moderate	Antagonize the effect of Biperiden when combined with Mesoridazine.	Schizophrenia [6A20]	[42]
Aripiprazole	DM3NUMH	Moderate	Antagonize the effect of Biperiden when combined with Aripiprazole.	Schizophrenia [6A20]	[27]
Iloperidone	DM6AUFY	Moderate	Antagonize the effect of Biperiden when combined with Iloperidone.	Schizophrenia [6A20]	[27]
Paliperidone	DM7NPJS	Moderate	Antagonize the effect of Biperiden when combined with Paliperidone.	Schizophrenia [6A20]	[27]
Molindone	DMAH70G	Moderate	Antagonize the effect of Biperiden when combined with Molindone.	Schizophrenia [6A20]	[27]
Thiothixene	DMDINC4	Moderate	Antagonize the effect of Biperiden when combined with Thiothixene.	Schizophrenia [6A20]	[27]
Trifluoperazine	DMKBYWI	Moderate	Antagonize the effect of Biperiden when combined with Trifluoperazine.	Schizophrenia [6A20]	[27]
Asenapine	DMSQZE2	Moderate	Antagonize the effect of Biperiden when combined with Asenapine.	Schizophrenia [6A20]	[27]
Fentanyl	DM8WAHT	Moderate	Additive CNS depression effects by the combination of Biperiden and Fentanyl.	Sensation disturbance [MB40]	[19]
Pramlintide	DM0EZ9Q	Moderate	Altered absorption of Biperiden due to GI dynamics variation caused by Pramlintide.	Type-1/2 diabete [5A10-5A11]	[43]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Biperiden and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[17]
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Biperiden and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[20]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Biperiden and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[20]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Biperiden and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[17]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Biperiden and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[20]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] BDDCS applied to over 900 drugs
• [3] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] Evaluation of in vivo binding properties of 3H-NMPB and 3H-QNB in mouse brain. J Neural Transm. 1999;106(7-8):583-92.
• [7] Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
• [8] Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
• [9] Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460.
• [10] The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic dr... Psychopharmacology (Berl). 2009 Apr;203(2):295-301.
• [11] Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62.
• [12] Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60.
• [13] Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701.
• [14] Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31.
• [15] Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42.
• [16] Algeri S, Cerletti C, Curcio M, et al. "Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and man." Eur J Pharmacol 35 (1976): 293-9. [PMID: 1248506]
• [17] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [18] Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
• [19] Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
• [20] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [21] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [22] Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
• [23] Multum Information Services, Inc. Expert Review Panel.
• [24] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [25] Product Information. GenESA (arbutamine). Gensia Inc, San Diego, CA.
• [26] Linnoila M "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol 6 (1973): 107-12. [PMID: 4588850]
• [27] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
• [28] Cerner Multum, Inc. "Australian Product Information.".
• [29] Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
• [30] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [31] Product Information. Nizoral (ketoconazole). Janssen Pharmaceutica, Titusville, NJ.
• [32] Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798]
• [33] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
• [34] Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
• [35] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
• [36] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [37] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [38] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [39] Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
• [40] Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON.
• [41] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [42] Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967): 1112-3. [PMID: 6021058]
• [43] Product Information. Symlin (pramlintide). Amphastar Pharmaceuticals Inc, South El Monte, CA.